InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,944.24
(
0.09%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: ghmm post# 149680

Sunday, 09/30/2012 7:44:41 PM

Sunday, September 30, 2012 7:44:41 PM

Post# of 251706
THLD - TH-302 data was presented at ESMO which showed a statsig 6mo PFS vs 3.6mo for gemcitabine alone, however the toxicities, especially at the 340mg level, are going to prove problematic.
http://biotechstrategyblog.com/2012/09/esmo-2012-th-302-pancreatic-cancer-survival-data-fails-to-impress.html/
Also, nice blurb at the end re: abraxane/CELGZ

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up